Samsung Biologics Offers $1.8 Billion for PolyPeptide: A Significant Move in Biotech Industry, ETPharma
Bengaluru: South Korea’s Samsung Biologics will launch a 1.46 billion Swiss francs ($1.81 billion) all-cash bid for Swiss…
Samsung Biologics to acquire PolyPeptide in $1.8 billion deal | World News
Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the…
SK Pharmteco Completes Obesity-Drug API Plant, Sets Up Peptide CDMO Clash With Samsung
View of SK Biotek’s Sejong plant, a subsidiary of SK Pharmteco. Photo courtesy of SK Pharmteco SK Biotek,…
Samsung Biologics to acquire PolyPeptide in $1.8 billion deal | World News
Shares of Samsung Biologics declined as much as 3.3% in Seoul on Monday. PolyPeptide shares jumped as much…
Samsung Biologics Acquires PolyPeptide for 2.7 Trillion Won, Expanding Growth Axis Beyond Antibodies
PolyPeptide Group’s India (Ambernath) plant. Photo courtesy of Samsung Biologics Samsung Biologics’ (207940.KS) acquisition of Swiss peptide contract…
Samsung Biologics Secures Peptide Capacity in Bid to Lead Obesity Drug CDMO
Samsung Biologics (207940.KS) has made the largest investment in the history of Korean pharmaceutical and biotech mergers and…
Samsung Biologics to acquire PolyPeptide Group in CHF 1.46 billion deal
Samsung Biologics has announced an all-cash public tender offer to acquire 100% of the fully diluted share capital…
[Medical Bio Board] Samsung Biologics acquires PolyPeptide Group in 2.7 trillion won deal
Panoramic view of PolyPeptide Group’s manufacturing plant in India. Provided by Samsung Biologics ■ Samsung Biologics is entering…
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).…
Samsung Biologics Offers $1.8 Billion for PolyPeptide: A Significant Move in Biotech Industry, ETPharma
Bengaluru: South Korea’s Samsung Biologics will launch a 1.46 billion Swiss francs ($1.81 billion) all-cash bid for Swiss…
Samsung Biologics expands into peptides with $1.8b PolyPeptide deal
Korea’s biggest biopharmaceutical acquisition expands CDMO’s global manufacturing network, multi-modality capabilities Samsung Biologics BioCampus 1 in Songdo, Incheon…